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evelopment of a Safe and Effective
ediatric Dosing Regimen for Sotalol Based on
opulation Pharmacokinetics and Pharmacodynamics
n Children With Supraventricular Tachycardia
tephanie Läer, MD, PHD,* Jan-Peer Elshoff, PHD,* Bernd Meibohm, PHD, FCP,†
ochen Weil, MD, PHD,‡ Thomas S. Mir, MD,‡ Wenhui Zhang, PHD,† Martin Hulpke-Wette, MD§
üsseldorf, Hamburg, and Göttingen, Germany; and Memphis, Tennessee
OBJECTIVES The objective of this study was to develop age-specific dosage guidelines for sotalol in children
with supraventricular tachycardia (SVT) based on a population pharmacokinetic covariate
analysis, clinical trial simulations, and pharmacodynamics.
BACKGROUND A rapid onset of an effective and safe antiarrhythmic sotalol therapy, especially for infants and
neonates, is frequently delayed because of age-dependent interpatient variability in pharma-
cokinetics and pharmacodynamics.
METHODS Pediatric patients with SVT (mean age 3.51 years [range 0.03 to 17 years]) were analyzed
after oral sotalol doses of 1.0 to 9.9 mg/kg/day using population pharmacokinetic analysis and
clinical trial simulation (n  76), pharmacokinetic/pharmacodynamic modeling for QT
interval prolongation (n  32), and for the concentration–antiarrhythmic-response relation-
ship (n  15).
RESULTS Inter-individual differences in oral clearance and volume of distribution could largely be
attributed to size and weight differences, with an additional age effect on clearance in children
younger than one year. Neonates showed a higher sensitivity toward QTc interval prolon-
gation compared with older patients. In a subgroup of 15 patients, one-half of the patients
converted into sinus rhythm at sotalol trough levels of 0.4 g/ml and more than 95% at 1.0
g/ml. Dosing recommendations derived for different age groups based on these findings
were starting dose and target dose of 2 and 4 mg/kg/day for neonates, 3 and 6 mg/kg/day for
infants and children 6 years, and 2 and 4 mg/kg/day for children 6 years.
CONCLUSIONS This study provides an example for rational drug dosage in children that copes with
interpatient variability and can be easily switched to an individually guided therapy based on
effective sotalol trough levels. (J Am Coll Cardiol 2005;46:1322–30) © 2005 by the
American College of Cardiology Foundationp
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che performance of clinical drug investigations is currently
subject of intense debate focusing on issues related to
oving a traditional paradigm of confirmatory hypothesis
esting toward a learning-based new paradigm (1). This new
aradigm incorporates pharmacostatistical cutting-edge
echnology such as population pharmacokinetic (PK) and
harmacodynamic (PD) analyses and clinical trial simula-
ion to build a scientific framework for more rational,
fficient, and informative clinical drug investigations (1).
For drug investigations in the pediatric population, these
ssues are critically important and urgent. The pediatric
From the *Department of Clinical Pharmacy and Therapeutics, University Düs-
eldorf, Düsseldorf, Germany; †University of Tennessee Health Science Center,
epartment of Pharmaceutical Sciences, Memphis, Tennessee; ‡Department of
ediatric Cardiology, University Hospital Hamburg-Eppendorf, Hamburg, Ger-
any; and the §Department of Pediatric Cardiology, University of Göttingen,
öttingen, Germany. Financial support was given by the German Heart Foundation
Frankfurt, Germany) and the Bundesverband Herzkranke Kinder (Aachen, Ger-
any) to Dr. Läer. This study was part of the doctoral thesis of Dr. Elshoff, and Dr.
äer was a Heisenberg fellow of the German Research Foundation (DFG, Bonn,
ermany), both at the Department of Experimental and Clinical Pharmacology in
amburg.
Manuscript received January 13, 2005; revised manuscript received June 4, 2005,accepted June 13, 2005.opulation is characterized by a limited number of patients,
broad age range with different developmental stages,
ge-restricted windows for diagnostic and treatment strat-
gies, and an age-dependent sensitivity toward pharmaco-
ogic and toxicologic effects (2). All these burdens apply to
he drug treatment of children with supraventricular tachy-
ardia (SVT), which is the most common symptomatic
achycardia in childhood (3). The peak incidence of SVT is
ound in neonates and infants, who are particularly prone to
eveloping congestive heart failure during persistent SVT
4). Pharmacotherapy is the first-line intervention in neo-
ates and infants.
The antiarrhythmic sotalol is highly effective (80%) in the
reatment of various subtypes of SVT in children (5). As a
rst step, intense investigations were performed on sotalol
harmacokinetics, showing that sotalol follows the matura-
ion process of renal function in the developing child with
igher drug exposure in neonates and young infants (6–8).
ne dosing option derived was a dosing recommendation
alculated on the basis of body surface area (BSA) with an
2dditional adjustment for children below a BSA of 0.33 m
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erence on Harmonization, however, pediatric dosing rec-
mmendations should be based on body weight (9) because
f practicability and safety, as calculation errors of BSA are
ot uncommon in smaller children and infants. Body
eight-based dosing is recommended for other commonly
sed antiarrhythmics in pediatric therapy, such as digoxin,
ropranolol, amiodarone, and flecainide (10) and is also
esirable for sotalol.
Sotalol is known for its high proarrhythmic potential of
orsade de pointes tachycardia (11). The QT interval used
or risk assessment of a drug’s proarrhythmic potential (12)
rolongs linearly with increasing sotalol concentration (13).
he higher sotalol exposure in young children consequently
ed to higher QT intervals in this age group (6). But there
s evidence from animal data that developmental changes
nclude not only the maturation of the kidney but also the
aturation of myocardial potassium channels, which are the
otalol targets for the QT prolongation (5). Until now,
efinite data concerning QT interval as a developmental PD
arameter as well as a safety parameter have been lacking
6,14). Furthermore, investigations of the relationship be-
ween sotalol concentrations and antiarrhythmic efficacy are
acking in children, but should provide a target concentra-
ion needed for successful SVT management.
Thus, the present study had three objectives: 1) to
elineate developmental changes of the QT interval using a
K/PD modeling approach; 2) to define a target sotalol
oncentration for the effective suppression of SVTs in
ediatric patients based on the concentration/antiarrhythmic
ffect relationship; and 3) to develop practical and age-specific
osing recommendations for SVT management in children of
ifferent age groups on the basis of body weight.
ETHODS
tudy organization. A prospective multiple-dose PK/PD
tudy was conducted in accordance with the Declaration of
elsinki and subsequent amendments. The institutional
oard at each study site approved the research protocol.
arents, legal guardians, or, when appropriate, patients
lder than seven years gave written informed consent.
atients. Children older than one week and below 18 years
f age with incessant or periodic SVT due to Wolff-
arkinson-White syndrome, concealed accessory pathway,
Abbreviations and Acronyms
AV  atrioventricular
BSA  body surface area
COES  COncentration Efficacy of Sotalol study
ECG  electrocardiogram
GFR  glomerular filtration rate
PD  pharmacodynamic
PK  pharmacokinetic
SVT  supraventricular tachycardiatrioventricular (AV) node reentry, or atrial ectopic or Gunctional ectopic tachycardia who required long-term an-
iarrhythmic intervention were included in the study. The
atients had to have two or more episodes of SVT. Failure
o respond to antiarrhythmics other than beta-receptor
lockers or sotalol in the past was not considered an
xclusion for this study. Patients were excluded or sotalol
herapy was discontinued if any of the following criteria
ere present or developed: marked left ventricular dysfunc-
ion (ejection fraction below 25%, shortening fraction below
5%); sinoatrial node dysfunction with age-inappropriate
esting sinus bradycardia below 100 beats/min for new-
orns, 80 beats/min for infants, and 60 beats/min for
hildren and adolescents; sinus pauses lasting longer than
.5 s; AV block grade 2 or 3 unless paced; PR0.24 s, QRS
0.18 s, QTc prolongation (15) of more than 470 ms (16);
ncreased frequency and duration of tachycardia phases with
ncreasing dose; doubling of serum creatinine from the start
ny time through the end of sotalol therapy; any abnormal
oncentrations of serum potassium, sodium, calcium, or
agnesium (reference values in mmol/l: 3.5 to 4.8, 135 to
50, 2.2 to 2.65, and 0.75 to 1.05, respectively); significant
nderlying renal, hepatic, gastrointestinal, or hematopoietic
ysfunction; infectious diseases; obstructive airway disease;
llergies related to medication; inability to tolerate age-
ppropriate food or the required study procedures (e.g.,
aintaining vascular access for repeated blood sampling);
rescription of drugs that influence QT-interval such as
miodarone, quinidine, disopyramide, or procainamide;
rugs influencing AV conduction such as verapamil or
iltiazem; any beta-receptor blocker; and digitalis intoxica-
ion. Digoxin was accepted as comedication if the patient
ad already received digoxin before starting the inpatient
onitoring phase. The following laboratory tests were
erformed for all children before the PK investigations:
omplete blood count with differential blood count, blood
rea nitrogen, serum creatinine, serum glutamic pyruvic
ransaminase, serum glutamic oxalacetic transaminase, alka-
ine phosphatase, total bilirubin, serum albumin, potassium,
odium, calcium, and urinalysis. An analysis of all concur-
ent medications for possible drug interactions with sotalol
as made before patient enrollment.
tudy design and treatment. Hospitalized patients at the
niversity hospitals in Hamburg and Göttingen received
otalol orally with a starting dose of 2 mg/kg/day divided in
hree equal parts every 8 h. All patients were hospitalized for
t least 3 days before the PK investigation to ensure regular
edication intake. In the morning, each patient was given
n age-appropriate breakfast in amount and composition
onsisting of at least milk, tea or coffee, two slices of bread,
r two rolls with jelly 30 min before sotalol administration.
reastfed pediatric patients received oral sotalol either 30
in before or 2 h after the breastfeeding. Patients received
heir morning dose of oral sotalol as a single capsule in
atient-specific strength. These capsules were prepared out
f Sotalex tablets (Bristol-Myers Squibb GmbH, Munich,
ermany) and lactose by the hospital pharmacy and were
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Pediatric Sotalol Dosing Regimen in Tachycardia October 4, 2005:1322–30rovided during the whole hospital stay. The content of the
otalol capsule was administered to the patient with an
ge-appropriate amount of water or tea. Complete ingestion
f the study medication was ensured by inspection of the
ral cavity and close supervision of the patient by the
esearch fellow (J. P. E.).
The dose was increased every third day by 2 mg/kg until
reatment was considered partially or completely effective or
f 10 mg/kg/day was reached. All patients were kept on
ontinuous electrocardiogram (ECG) monitoring through-
ut their hospital stay. A subset of 15 patients (COES:
Oncentration Efficacy of Sotalol study) with the same
nclusion criteria as the other patients were started on 1
g/kg/day and treated with smaller incremental dosages of
mg/kg every third day. In addition to the routine contin-
ous ECG monitoring, 12-lead ECGs were recorded every
ay to document frequency of arrhythmia. A 24-h ECG
as obtained before start of therapy and after conversion
nto sinus rhythm. The maximum dosage was 10 mg/kg/day
hen no limiting side effects occurred. Pharmacokinetics of
otalol were evaluated at the fourth day by performing a
lasma concentration profile. Serum creatinine concentra-
ions and electrolytes were regularly monitored before and
uring therapy.
nd points and assessments. Complete effectiveness was
efined as conversion of arrhythmia into sinus rhythm. The
riterion for partial effectiveness in patients was a lowering
f the heart rate to age-appropriate values. These end points
ad to be maintained for a minimum of three days. The
arget outcome parameter in the COES study patients was
omplete effectiveness. The QT-interval prolongation was
ssessed from 12-lead ECGs before treatment and in
0-min intervals during the 12-h plasma concentration
rofile. A single research scientist read all recordings and a
econd cardiologist was blind to the patient identification
nd to the sequence of ECGs. No differences were noted
sing a Bland-Altman test between the two readings
15,16).
ample collection and procedures. The plasma concen-
ration profile started at 8:00 AM. Blood samples of 300 to
00 l were collected before drug administration and at 1,
, 3, 4, 6, 8, and 12 h following the oral dose. During that
ay, one dose in between the 12-h profile was skipped.
otalol was determined by a non-stereoselective high-
erformance liquid chromatography assay with fluorimetric
etection (17).
K/PD modeling of the QT interval. The QT intervals
f lead II were averaged from three to five consecutive sinus
eats at each recording time. The same electrocardiographic
pparatus was used in both institutions (Cardiovit AT-2
lus, Schiller, Switzerland) at a chart speed of 50 mm/s and
n amplitude of 10 mm/mV. Patients had rested for 10 min
n the supine position. Tracings with irregular RR interval,
at T-wave, and motion artifacts were excluded. There were
o patients with pre-excitation syndromes for the ECG
nalysis. End of the T-wave was determined by manual srawing of a tangent to the steepest portion of the down-
loping T-wave. The tangent’s intersection with the isoelec-
ric line marked the end of the T-wave.
Because heart rate is elevated in the neonatal and infant
eriod, neither Bazett’s (18) nor Fridericia’s (19) formula
ight suffice for correcting the QT interval for short
ardiac-cycle length. According to the formula QT 
Tc · RRb, a population-derived correction mode
QTcPOP) was fitted to the baseline neonatal/infant (up to 2
ears) and to children/adolescents (2 years) data with b 
.51 and b  0.37, respectively, and compared to Bazett’s
QTcB) and Fridericia’s formula (QTcF). Basal QTcPOP
ntervals (in ms) and corresponding heart rates (in beats/
in) were 401  19 and 124  13 (neonates, n  9), 411
26 and 130  29 (infants, n  6), 387  15 and 78 
1 (children, n  10), and 403  10 and 84  22
adolescents, n  3). All relations between corrected QT
ntervals and sotalol concentrations were best described by a
inear PK/PD model (20). The slope of the linear effect
odel gave the individual increase in the QTc interval per
g/ml sotalol in plasma as a measure for the individual
ensitivity (dQTc).
evelopment of the dosing schedule. Patient covariates
redictive for individual PK parameters of sotalol were
dentified by a population PK approach simultaneously
nalyzing the 76 sotalol plasma concentration-time profiles.
harmacokinetic parameters were estimated by nonlinear
ixed effects modeling (NONMEM V, Globomax,
anover, Maryland) with first-order conditional estimation
FOCE) and - interaction. After assessing a base model,
he following covariates were entered by stepwise forward
egression and backward elimination: age, weight, height,
SA (21), gender, GFR (22), arrhythmia diagnosis, and
igoxin comedication. The significance was tested using a
og-likelihood ratio test for differences in objective function
etween hierarchical models. Finally, covariate specific
opulation-PK parameters were calculated on the basis of
ndividual covariate sets of study subjects and the derived
nal population pharmacostatistic model.
This model was subsequently used to perform simulations
TRIAL SIMULATOR, Pharsight, Mountain View, Cal-
fornia). A covariate model with a joint distribution between
ge and weight was developed with an age-adjusted variance
ovariance matrix of the study population to account for the
nlinearity of the correlation between age and weight. The
oncentration response relation was best described by a
ogistic regression model, P  ex/(1  ex), where P is the
robability of arrhythmia suppression (response) and x the
rug effect (2.4  10.1 · sotalol conc.1.9). In a meta-
esign, 1,000 patients received 1, 2, 3, 4, 5, 6, 7, or 8
g/kg/day with a dosing interval of 8 h for four days. In 20
eplicates, sotalol trough concentrations at steady state were
imulated. Sensitivity analyses were performed for the co-
ariance, the drug, and the response model. As a posterior
redictive check, simulated sotalol oral clearances of the
imulated patients were compared with the measured sotalol
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October 4, 2005:1322–30 Pediatric Sotalol Dosing Regimen in Tachycardiaral clearances in the studied patient population. A dosing
chedule for effective sotalol pharmacotherapy was proposed
n the basis of the simulated sotalol trough concentrations
t steady state and the exposure-response relationship de-
ived from the COES study.
tatistical analysis. Pharmacodynamic parameters of pedi-
tric patients were analyzed using analysis of variance
ANOVA) with post hoc analysis of Tukey’s honestly
ignificant difference test and least significant difference test
o account for differences of these tests concerning power
nd control of the experiment-wise type I error (23).
ossible age dependency was carried out using linear and
on-linear least-square regression techniques using a Spear-
an’s rank correlation coefficient. A p value below 0.05 was
onsidered significant. Analyses were performed using SPSS
.0 (SPSS Inc., Chicago, Illinois).
ESULTS
emographics and baseline characteristics. Results are
eported as mean values  SD unless stated otherwise.
eventy-six patients were subcategorized into neonates (1 to
8 days, n  12), infants and toddlers (29 days to 23
onths, n  33), children (2 to 12 years, n  26), and
dolescents (13 to 17 years, n  5) and included in the
opulation-PK analysis to delineate a dosing schedule.
hirteen premature infants were included in the study.
one of the patients had congenital heart disease. A subset
f 15 patients (the COES study; 6 neonates, 3 infants, 5
hildren, 1 adolescent) participated in a study to show the
elationship between sotalol plasma concentrations and
onversion into sinus rhythm (Table 1). Pharmacokinetic/
harmacodynamic analyses for age-related changes of the
T intervals were performed in 32 age- and gender-
atched patients (9 neonates, 8 infants, 12 children, and 3
dolescents). All subsets of patients showed comparable
aseline demographic data. None of the patients had ab-
ormal serum electrolytes of potassium, sodium, calcium, or
able 1. Demographic Characteristics of Pediatric Patients
Group n
Gender
(F/M)
Age
(yrs)
Height
(cm)
B
otal (ALL) 76 27/49 3.51 (4.53) 88 (37)
OES
Neonates 6 1/5 0.05 (0.01) 51 (2)
Infants and toddlers 3 2/1 0.46 (0.28) 64 (16)
Children 5 3/2 7.17 (3.42) 124 (24)
Adolescents 1 1/0 13.01 142
Total COES 15 7/8 3.80 (1.20) 84 (40)
LL minus COES
Neonates 6 2/4 0.05 (0.02) 49 (10)
Infants and toddlers 30 8/22 0.61 (0.47) 66 (10)
Children 21 9/12 6.70 (3.20) 118 (24)
Adolescents 4 1/3 14.5 (2.2) 168 (17)
otal ALL minus
COES
61 20/41 3.54 (4.54) 89 (37)
ata reported as mean (SD).
ALL 76 plasma concentration profiles of pediatric patients; BSA body surfaceltration rate; SVT  supraventricular tachycardia; VES  ventricular ectopic tachycardiaagnesium and remained within the reference range at any
ime of the study. Mean sotalol dosages were 3.6  1.8
g/kg/day with a range from 1 to 9.9 mg/kg/day.
elation between sotalol plasma concentrations and an-
iarrhythmic efficacy. There were 15 patients (7 female, 8
ale) who met the inclusion criteria for this part of the
tudy (Table 1). In one child, sotalol had to be reduced from
to 5 mg/kg/day because of QTcB prolongation above 470
s. The 24-h ECG recordings obtained after conversion
nto sinus rhythm showed three patients with some rare
vents of supraventricular extrasystole and ventricular extra-
ystole. One patient showed a short period of sinus tachy-
ardia and two patients showed a 2-min period of SVT. In
ll patients, sotalol therapy was continued up to six months.
rrhythmia recurrence was noticed in three patients after
wo months of medication. No proarrhythmic effects such as
orsade de pointes tachycardia or bradycardia were noted.
lasma concentration-response relations of sotalol trough
evel conversions of each patient are shown in Figure 1. The
ine shows the probability of patients converting into sinus
hythm (response) at trough sotalol concentrations accord-
ng to an 8-h dosing schedule. Effective minimal sotalol
oncentrations ranged from 0.21 to 1.05 g/ml. The cor-
esponding maximal plasma concentrations ranged from
.29 to 2.1 g/ml. The concentration predicted for a 50%
robability to convert into sinus rhythm was 0.4 g/ml
otalol and for a more than 95% probability was 1.0 g/ml.
nfluence of age on sotalol’s QT interval prolongation. First,
he patients’ QT-RR intervals under sotalol therapy were
lotted as presented in Figure 2A. The individual QT-RR
nterval of a 50-day-old infant and an 8-year-old child with
2 and 36 QT-RR intervals, respectively, are marked. Then
he heart-rate-corrected QT intervals as increase above
aseline were plotted versus their respective sotalol concen-
rations (Fig. 2B) to detect PD differences. The QTc
nterval showed a steeper increase in neonates compared
ith the older patients. Statistical calculations of the indi-
eight
g)
BSA
(m2)
GFR
(ml/min/1.73m2)
Arrhythmia
(SVT/VES)
Digoxin
(n)
17.1) 0.60 (0.44) 101 (58) 74/2 16
0.4) 0.23 (0.02) 52 (17) 6/0 0
3.1) 0.31 (0.13) 84 (37) 3/0 0
12.4) 0.96 (0.31) 176 (28) 5/0 0
9 1.09 166 1/0 0
13.8) 0.55 (0.41) 107 (63) 15/0 0
0.7) 0.21 (0.04) 39 (21) 6/0 1
2.3) 0.35 (0.09) 76 (29) 30/0 12
15.6) 0.92 (0.34) 132 (45) 19/2 4
22.7) 1.62 (0.40) 165 (30) 4/0 0
17.9) 0.62 (0.45) 99 (50) 59/2 16
OES patients for the sotalol concentration effect relationship; GFR glomerularody W
(k
16.0 (
3.6 (
5.6 (
27.4 (
3
13.7 (
3.2 (
6.9 (
26.7 (
57.4 (
16.6 (
area; C
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Pediatric Sotalol Dosing Regimen in Tachycardia October 4, 2005:1322–30idual sotalol-normalized increase in QTc interval (dQTc)
ndicated a 160% to 280% higher sensitivity in the neonates
ompared with infants, children, and adolescents (r  0.51,
 0.003) (Figs. 2C and 3). Sotalol concentrations in the
ndividual patients ranged between 0.21 and 2.05 g/ml.
here was no evidence of a systematic bias in the depen-
ency between the concentration range, age, or dQTc
lopes.
evelopment of the dosing schedule. The final popula-
ion pharmacostatistic model for sotalol with parameter
oint estimates and their variability is summarized in Table
. Sotalol pharmacokinetics were best described by a one-
ompartment base model with first-order input and elimi-
ation. Body weight, height, and BSA were identified as the
ost relevant predictors for oral clearance and volume of
istribution. Owing to their high collinearity, inclusion of
ore than one of these size covariates in the model did not
urther improve predictability. Inclusion of age for the
rediction of sotalol clearance in patients younger than one
ear prevented overprediction of clearance in this age group
Fig. 4). All other covariates were not significant predictors
or sotalol pharmacokinetics once size and age were
ncluded.
Sotalol concentrations were simulated based on simulated
ral clearances. The distribution of the simulated oral
learances was similar compared with the measured clear-
nces (mean  SD: 2.66  1.76 ml/min and 2.47  1.89
l/min, respectively) (Fig. 4). Simulated sotalol trough
oncentrations were sorted according to age group and daily
ose (Fig. 5A). Analyses of the replicates showed an intra-
nd inter-day variability lower than 3%. Figure 5B illustrates
he patient fraction with arrhythmia suppression according
o the simulation. The range of daily doses is necessary for
chieving a 50% probability (start dose) and more than 95%
robability to respond to sotalol therapy in nearly all
atients (target dose). For safety reasons, the daily dose was
imited assuming that nearly all patients (upper limit of the
ox-plot analysis) do not exceed a trough level of 1 g/ml.
igure 1. Probability of arrhythmia suppression in the 15 children with
upraventricular tachycardia (COES study patients) versus sotalol trough
oncentration under steady-state conditions and an 8-h dosing interval.
illed circles  6 neonates (28 days).o avoid putting children at risk with an adult dosing ichedule (every 12 h), an 8-h dosing interval was chosen.
his ensured a similar degree of fluctuation between trough
nd maximal sotalol concentrations in children compared
ith adults (1.1 in adults; 0.8 in the pediatric population).
Table 3 shows a delineated optimized and an estimated
linically useful dosing schedule. To demonstrate its useful-
ess we classified retrospectively the effective dosages of
atients according to these dosing ranges. Seventy-five
ercent of neonates (n  12) had effective dosages between
and 4 mg/kg/day and 8% below this range. A total of 58%
f infants younger 6 months (n  19), 64% of infants
etween 6 months and 2 years (n  14), and 70% of
hildren between 2 and 6 years (n  10) had effective
osages between 3 and 6 mg/kg/day: 21%, 29%, and 20%,
igure 2. (A) QT-RR (open circles) intervals of patients under sotalol (1
o 9.9 mg/kg/day) therapy. Filled circles  a 50-day-old infant (4.1
g/kg/day); large filled circles  8-year-old child (2.9 mg/kg/day). Solid
ine  fit of baseline neonate/infant QT-RR data dotted line: a fit of
aseline children/adolescent data. (B) Differences of QTcPOP intervals
rom baseline in neonates (filled circles) and all other pediatric patients
open circles) versus sotalol concentration. (C) Sensitivity of the QTc
nterval prolongation towards sotalol (dQTcPOP).
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October 4, 2005:1322–30 Pediatric Sotalol Dosing Regimen in Tachycardiaespectively, below this range. Ninety-five percent of chil-
ren older than 6 years (n  21) were effectively treated in
he range between 2 and 4 mg/kg/day; none of the patients
ere below this range. In summary, between 78% and 95%
f patients were effectively treated according to this retro-
pective analysis of the patients’ effective dosages.
igure 3. Mean  SD QT interval prolongation normalized for sotalol
oncentrations. (A) dQTcPOP; (B) dQTcF; (C) dQTcB in neonates (28
ays), infants (2 years), and children and adolescents (15 years). p
alues according to ANOVA with Tukey’s honestly significant difference
est (#) and least significance difference test (°).
Table 2. Final Population Pharmacokinetic M
Parameter Model
CL/F‡ [l/h] 1 · (weight[kg]/7.3)
2
For age 1 yr: 1 · (weight[kg]/7.3
Vd/F§ [l] 4  5 · (weight[kg]  7.3)
ka [h1] 6  (CL/Vd)
tlag¶ [h]
Residual error Proportional: CV 8.8%; additive: S
*The parameters describe a one-compartment pharmacokinetic m
can be described by the following expression for the concentrat
C
F·Dose·ka
Vd·kaCLVd
·
†Interindividual variability. ‡Oral clearance. §Volume of dis
constant. ¶Lag time: time difference between drug administr
deviation.dverse events. Of 76 patients, three had heart rate-
orrected QTcB intervals exceeding 470 ms with subsequent
ose reduction.
ISCUSSION
he results of the study provide an age-specific, practical,
nd safe dosing regimen based on body weight and age for
otalol in pediatric patients with SVT. This could contrib-
te to a more rapid and safer antiarrhythmic drug treatment
or children and may prevent hemodynamic instability with
ubsequent long lasting hospitalizations of patients. This
osing regimen is based on the 50% and 95% probability to
onvert patients into sinus rhythm. Using dose simulations,
hree clinically useful age categories were delineated, from 2
g/kg/day up to 6 mg/kg/day, with an 8-h dosing interval.
he study results raised concern about a safe use of the drug
n neonates. The QT interval was on average twice as long
n neonates under sotalol compared with older children.
This is the first report on the therapeutic range of sotalol
n SVT in the pediatric population. In pediatric patients
ith SVT, the minimal effective sotalol plasma concentra-
igure 4. Measured (closed diamonds) and model predicted oral sotalol
learance based on body weight (open diamonds). Median (solid line) and
he 10th and 90th percentile (dashed line) of 1,000 simulated data sets.
Estimate (%CV) IIV† (%CV)
1 2.08 (6.5) 25.9
age[yr]/0.76)3 2 0.580 (14.4)
3 0.248 (22.3)
4 15.8 (5.4) 27.0
5 1.51 (10.7)
6 0.895 (9.5) 89.7
7 0.445 (18.0) 93.1
.8 ng/ml
ith first-order input and elimination, and lag-time. This model
, versus time, t:
(ttlag) eka·(ttlag)
on corrected for bioavailability. First-order absorption rate
nd modeled first appearance of sotalol in plasma. #Standardodel*
)2 · (
D# 24
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hildren has had a history of previous resistance to beta-
eceptor blockers.
Sotalol concentrations, however, and antiarrhythmic re-
ponse were investigated in depth in an older study pub-
ished by Wang et al. (13) in 11 adults with ventricular
achyarrhythmia with a mean age of 55 years and a high
requency of ventricular arrhythmias. Eight of these patients
ad previously been resistant to beta-blocker receptor ther-
py. Their effective sotalol trough levels ranged from 0.34 to
.44 g/ml. Thus, although the effective concentration
ange seems higher in adults compared with children, a
omparison between both population groups is limited by
he etiology of arrhythmia, underlying heart disease, and
revious resistance to beta-receptor blocking therapy. This
as an open uncontrolled study, and spontaneous remission
f tachycardia might bias the results. The natural cause of
he disease, however, has been sparingly investigated, but
pontaneous remission is quite unlikely in the short term
4), supporting the reliability of the results.
In the present study, sotalol had a greater QT-prolonging
ffect in neonates than in non-neonates. In older children,
T prolongation approximated adult values. Serum electro-
ytes were not different in these patients, and a stereoselec-
igure 5. Black box plots and hatched bars indicate recommended dosing
ange. (A) Simulated sotalol trough concentrations (125 patients per group
nd dose level) for pediatric patients with supraventricular tachycardia.
ines indicate 50% and more than 95% efficacy. (B) Patient fraction with
0% and more than 95% probability of arrhythmia suppression. Arrows
ndicate start and target doses.ive disposition of sotalol cannot been assumed (24). Al-hough this confirms previous investigations (6), the present
esults extend our knowledge. Whereas Saul et al. (6)
ttributed the age-dependent differences of QT prolonga-
ion to the maturation of the kidneys, we provide evidence
hat the maturation of myocardial potassium channels, in
art may explain these longer QT prolongations in young
hildren. This is of importance because there is a common
echanism of drug-induced QT prolongation (12), mean-
ng that not only sotalol but also other cardiac or noncardiac
rugs with the same mechanism of action might behave
imilarly in neonates. Hence, the results might explain
onflicting data concerning QT interval prolongation in the
ediatric population reported from other drugs, such as
isapride (25,26), or it might be helpful in predicting such
ffects for future applications of drugs (12).
Saul et al. (8) did not detect PD age-dependent differ-
nces in QT interval prolongation. In the present study,
otalol had a greater QT prolonging effect in neonates than
n non-neonates. This might be a matter of sample size
ecause PD data show high intersubject variability. An
ncrease in sample size, especially in neonates, from 6 of 22
atients (8) to 9 of 32 patients (our investigation) and a rich
K/PD dataset of the individual patients revealed a higher
ensitivity of QT interval prolongation of very young chil-
ren toward sotalol in the present study. Sotalol is neither
etabolized nor bound to plasma proteins; the main elim-
nation route is passive glomerular filtration (24). A stereo-
elective disposition with relatively higher d-sotalol concen-
rations in neonates is unlikely, because stereoselective
nalysis of sotalol plasma concentrations had not supported
his possibility. Sotalol leads the list of antiarrhythmic drugs
ith dose-dependent increases of torsade de pointes tachy-
ardia (11). Given the higher sensitivity for sotalol-induced
T prolongation in neonates, we recommend that sotalol
e used only with careful QTc monitoring, especially in this
ge group. Sotalol’s incidence of torsade de pointes tachy-
ardia in the pediatric population has not been reported, but
systematic research for the safety of sotalol therapy in
eonates should be performed. The robustness of the QT
ata analysis is supported by nearly identical results com-
aring the population-derived mode with Bazett’s and
ridericia’s correction modes for all patients. The
able 3. Age-Specific Dose Regime for Sotalol in Children
ith Supraventricular Tachycardia
8-h Dosing Interval
Group
Optimized Dose of
Sotalol According to the
Trial Simulation
(Start/Target)
(mg/kg/day)
Recommended
Clinically Useful
Dose of Sotalol
(Start/Target)
(mg/kg/day)
eonates 2/4 2/4
nfants 6 months 3/5 3/6
nfants 2 yrs 3/6 3/6
hildren 6 yrs 3/5 3/6
hildren 6 yrs 2/3 2/4
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hould demonstrate the coherence of the QT-RR relation-
hip across a broad age range in the pediatric population.
The adequacy and reproducibility of population pharma-
okinetics is underlined by the fact that size and age were
dentified as the only predictors of sotalol pharmacokinetics
n pediatric patients, in agreement with a previously re-
orted study (14). Glomerular filtration rate did not further
mprove the final model, most likely because of the absence
f subjects with pathophysiologically impaired renal func-
ion. Body weight and BSA were similarly good predictors
f oral sotalol clearance. For children with low BSA or low
ody weight, age as an additional covariate improved the
odel further, accounting for the postnatal maturation of
he kidneys. In the context of previous investigations (6,8),
ome points concerning the depicted covariates of age and
ody weight as a basis for the development of the dosing
chedule have to be mentioned. According to the exclusively
enally eliminated sotalol, oral sotalol clearance and GFR
re strongly related (6,27). Body weight and BSA were also
trongly related to the GFR in this population. The Food
nd Drug Administration dosing recommendations derived
dosing schedule and a calculation formula based on BSA
ith an additional factor for children below a BSA of 0.33
2 taken from a nomogram. For simplicity, practicability,
nd in accordance with other commonly used antiarrhyth-
ic drugs in children (10), we chose body weight as a basis
or the development of the dosing schedule and added age
s a second covariate. Both of these covariates are easily and
eliably accessible with a minimum chance of calculation
rrors at bedside.
A limitation of the developed dosing schedule is that only
ubjects with normal renal function were part of the patient
opulation. Because patients with renal failure were not
nvestigated in this study, this aspect needs further investi-
ation. Sotalol should therefore be used with caution and
ith plasma concentration monitoring as a guide in patients
ith renal disease.
In conclusion, in our clinical drug investigation we
earned about the precise quantitative relation between drug
xposure and response and how this relates to the patients’
ovariates. Only this quantification enabled us to simulate a
linical trial, to predict the drug response, and, finally, to
elineate a dosing regimen. This research should provide a
afer and more rapid antiarrhythmic pharmacologic treat-
ent in children with SVT. Having established effective
otalol trough levels, the delineated dosing guideline can be
asily switched to an individually guided therapy on the
asis of sotalol trough levels. Better knowledge about
ffective drug levels may also aid in the decision-making
egarding when to discontinue sotalol and try other antiar-
hythmic drugs.
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